Ranbaxy may have to pay huge fine, again
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility
Ranbaxy Pharmaceuticals
-
Ranbaxy gets nod to sell popular generic in US
RANBAXY Laboratories has got the exclusive rights to market a generic version of Japanese firm Eisai Co
-
Lupin, Ranbaxy Labs sue each other over patent disputes
<br /><p>LUPIN Limited and Ranbaxy Laboratories along with its parent company Daiichi Sankyo have slapped patent infringement charges against each other to stop one another from launching low-cost versions of their respective original drugs in the US.</p>
-
Ranbaxy shifts research arm to Daiichi
Indian Company To Become Pure Generics Drugmaker; To Retain Research Activity For Anti-Malarial Drug RANBAXY Laboratories has transferred its research division for new drugs to Japan
-
Delhi HC rejects BMS plea to ban Ranbaxy generic
THE Delhi High Court has turned down a plea by US pharma major Bristol-Myers Squibb (BMS) to ban India
-
Ranbaxy settles patent dispute with Takeda
RANBAXY Laboratories on Monday announced it has settled a patent dispute with Takeda Pharmaceutical allowing the Gurgaon-based drugmaker to launch its generic tablets of Takeda
-
Ranbaxys failure to get USFDA nod to hurt co
RANBAXY Laboratories
-
Ranbaxy in talks to buy Bangalore vaccine firm
Deal Could Be Aimed At Getting Access To Technology Or Manufacturing Platform Khomba Singh NEW DELHI
-
EU officials raid Ranbaxy French unit
Move Part Of Probe On Drug Units Which Delay Launch Of Generics Our Bureau NEW DELHI INDIA
-
Pharma firms may have to return Rs 2,038-cr overcharged amount
DRL, Cipla Among Cos Found Involved In Overcharging By Drug Price Regulator
-
Riding High on Tamiflu
With demand for the antidote to H1N1 infection peaking across the world, the select Indian pharmaceutical companies are ramping up production of Tamiflu or its generic version.